Short Interest in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Decreases By 21.8%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totaling 13,039 shares, a decrease of 21.8% from the December 15th total of 16,674 shares. Based on an average daily volume of 29,226 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.4% of the company’s shares are short sold. Currently, 0.4% of the company’s shares are short sold. Based on an average daily volume of 29,226 shares, the days-to-cover ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Friday, October 31st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.00.

Kiora Pharmaceuticals Stock Performance

Shares of Kiora Pharmaceuticals stock traded down $0.01 on Friday, reaching $2.18. 3,777 shares of the company’s stock were exchanged, compared to its average volume of 27,917. The company has a market capitalization of $8.02 million, a P/E ratio of -1.04 and a beta of -0.89. Kiora Pharmaceuticals has a 52 week low of $1.76 and a 52 week high of $4.18. The firm’s 50-day moving average is $2.06 and its two-hundred day moving average is $2.48.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its earnings results on Friday, November 7th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.73. On average, analysts expect that Kiora Pharmaceuticals will post 1.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 44,573 shares of the company’s stock, valued at approximately $125,000. Citadel Advisors LLC owned approximately 1.21% of Kiora Pharmaceuticals at the end of the most recent reporting period. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.